Chembio diagnostics awarded $3.2 million contract from the cdc for development and clinical validation of dual-path platform syphilis screen & confirm assay

Hauppauge, n.y., sept. 06, 2022 (globe newswire) -- chembio diagnostics, inc. (chembio) (nasdaq: cemi), a leading point-of-care diagnostics company focused on infectious diseases, today announced it was awarded a $3.2 million contract from the centers for disease control and prevention (cdc) for the development and clinical validation of a rapid point-of-care (poc) diagnostic test for syphilis.
CEMI Ratings Summary
CEMI Quant Ranking